Overview

An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer

Status:
Completed
Trial end date:
2020-05-27
Target enrollment:
Participant gender:
Summary
Phase 1 study to evaluate the safety and effect of Gedatolisib and PTK7-ADC for the treatment of triple negative breast cancer
Phase:
Phase 1
Details
Lead Sponsor:
Kathy Miller
Treatments:
Gedatolisib